Nanobiotix S.A. (FRA:5NR)

Market Cap	881.38M
Revenue (ttm)	10.16M
Net Income (ttm)	-51.64M
Shares Out	n/a
EPS (ttm)	-1.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	23
Open	16.88
Previous Close	17.20
Day's Range	16.88 - 18.32
52-Week Range	2.53 - 27.70
Beta	n/a
RSI	53.21
Earnings Date	Nov 20, 2025

About Nanobiotix

Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBT...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2003
• Employees: 108
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5NR